Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Pandemic
99%
Randomized Controlled Trial
84%
Diseases
61%
Placebo
58%
Mycobacterium Bovis BCG
56%
Randomized Clinical Trial
54%
Prevalence
43%
HIV
40%
Observational Study
32%
BCG Vaccine
27%
Mycoplasma genitalium
27%
Chronic Disease
27%
Coronavirinae
27%
Messenger RNA
27%
Live Attenuated Influenza Vaccine
25%
SARS Coronavirus
22%
Vaccinia
16%
Live Vaccine
14%
Virus Infection
13%
Table Salt
13%
Cytokine
12%
Clinical Trial
10%
Chemotherapy
6%
Intervention Trial
6%
Mycobacterium Tuberculosis
6%
Immune Deficiency
6%
Bacterial Infection
6%
Adverse Event
6%
Prednisone
6%
Mucocutaneous Lymph Node Syndrome
6%
Inflammation
6%
Skin Manifestation
6%
mRNA Vaccine
6%
Severe Acute Respiratory Syndrome
5%
Vaccinia Vaccine
5%
Cross-Sectional Study
5%
Medicine and Dentistry
COVID-19
86%
Health Care
65%
Mycobacterium Bovis BCG
56%
Infection
42%
Immune System
40%
Human Immunodeficiency Virus
34%
Placebo
31%
Mycoplasma genitalium
27%
Prevalence
27%
Randomized Controlled Trial
27%
BCG Vaccine
27%
Randomized Clinical Trial
27%
Messenger RNA
27%
Influenza Vaccine
25%
Hazard Ratio
17%
Diseases
14%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Study Participant
11%
Virus Infection
10%
Table Salt
10%
Influenza Vaccination
8%
Cumulative Incidence
7%
Clinical Trial
7%
Cross Reaction
6%
Kawasaki Disease
6%
Serositis
6%
Skin Manifestation
6%
Sequela
6%
mRNA Vaccine
6%
Secretion (Process)
6%
Immunocompetent Cell
5%
Live Vaccine
5%
Infectious Disease
5%
Observational Study
5%
Nursing and Health Professions
Infection
27%
Hazard Ratio
17%
Health Care Personnel
15%
Placebo
15%
Influenza Vaccine
11%
Antibody Titer
5%
